BSD Reports Growing Interest in Hyperthermia Systems at American Society for Radiation Oncology (ASTRO) Meeting

  BSD Reports Growing Interest in Hyperthermia Systems at American Society for
  Radiation Oncology (ASTRO) Meeting

Business Wire

SALT LAKE CITY -- November 19, 2012

BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a
leading provider of medical systems that utilize targeted heat therapy to
treat cancer, today announced growing interest in hyperthermia at the 2012
international conference of the American Society for Radiation Oncology
(ASTRO). ASTRO is the largest radiation oncology society in the world, and the
annual conference is the premier worldwide scientific meeting in radiation
oncology. The theme of the 2012 meeting was “Advancing Patient Care Through
Innovation.”

BSD offers technologically innovative products that provide targeted heat
therapy for the treatment of cancer. Hyperthermia has been shown to be the
most potent radiosensitizing agent known to date and has demonstrated the
ability to increase the effectiveness of radiation and many chemotherapeutic
agents for certain tumors.

“Exhibiting at ASTRO allowed BSD to showcase the Company’s hyperthermia
technology to interested physicians and distributors throughout the world,”
stated Harold R. Wolcott, President of BSD Medical. “We were pleased with the
increased level of interest in hyperthermia shown by both the U.S. and the
international medical community and distributors.”

About ASTRO

ASTRO is the largest radiation oncology organization of its kind and has more
than 10,000 members. Their members include radiation oncologists, radiation
oncology nurses, medical physicists, radiation therapists, dosimetrists and
biologists, the medical professionals that are part of the medical teams that
treat more than 1 million cancer patients each year. ASTRO is committed to
excellence in patient care through a team-based approach to treatment.

About the BSD Hyperthermia Systems

The BSD-500 Hyperthermia System (BSD-500) is used to deliver therapeutic,
targeted heat therapy (hyperthermia) using either non-invasive (external) or
interstitial (internal) applicators. The BSD-500 has received U.S. Food and
Drug Administration (FDA) pre-market approval (PMA), which is the standard FDA
approval required to market Class III medical devices in the United States,
for the use of hyperthermia alone or in conjunction with radiation therapy for
the treatment of certain tumors. Clinical studies have shown that hyperthermia
delivered using the BSD-500 can significantly increase the effectiveness of
radiation therapy without a significant increase in toxicity for certain
tumors.

The BSD-2000 – developed and patented exclusively by BSD – delivers localized
therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The
BSD-2000 creates a central focusing of energy that can be electronically
focused to target the shape, size and location of the tumor, thus providing
dynamic control of the heating delivered to the tumor region. The BSD-2000 has
Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and
Drug Administration (FDA) for use in conjunction with radiation therapy for
the treatment of cervical cancer patients who are ineligible for chemotherapy.
The BSD-2000 also has CE (Conformité Européenne) Marking approval for the
commercial sale in Europe. CE Marking approval is also recognized in many
countries outside of the EU.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy delivered using focused
radiofrequency (RF) and microwave energy. BSD’s product lines include both
hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer
treatment systems, which have been in use for several years in the United
States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia) while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to ablate and destroy soft tissue. The Company has
developed extensive intellectual property, multiple products in the market and
well established distribution in the United States, Europe and Asia. Certain
of the Company’s products have received regulatory approvals in the United
States, Europe and China. For further information visit BSD Medical's website
at www.BSDMedical.com.

Statements contained in this press release that are not historical facts are
forward-looking statements, as defined in the Private Securities Litigation
Reform Act of 1995. All forward-looking statements are subject to risks and
uncertainties detailed in the Company's filings with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date on which such statements are made, and the Company undertakes no
obligation to update such statements to reflect events or circumstances
arising after such date.

Contact:

BSD Medical Corporation
Dennis Gauger, 801-972-5555
investor@bsdmc.com
fax: 801-972-5930
 
Press spacebar to pause and continue. Press esc to stop.